Upload
others
View
10
Download
0
Embed Size (px)
Citation preview
Dr Frank Thielmann Inolytix IGC Symposium, June 2015
The use of Inverse Gas Chromatography in formulation development and manufacturing of dry powder
inhalation products
Overview2
Introduction – Respiratory diseases and inhalation devices
Study I – Understanding of granulation behaviour
Study II – Morphology changes upon micronisation
Study III – Interaction of drug substance and propellant
Conclusions
Respiratory Diseases
COPD (Chronic Obstructive Pulmonary Disease) COPD is a general expression for various diseases
characteristics (phenotypes) There are predominately two phenotypes:
COPD is mainly caused by smoking (western world) and air pollution (developing world)
3
• Chronic Bronchitis (lung damage and inflammation in the large airways).
• Emphysema (lung damage and inflammation of the air sacs/ alveoli).
Source: Wikipedia
Inhaler device types Nebuliser (p)MDI DPI Reservoir Powder in Blister Capsule-based Active devices
4
Source: Wikipedia
Dry Powder Aerosol Delivery Systems
5
Expert System
Drug substance & formulation development/ manufacturing
Aerosol generation and delivery by inhalation device
Deposition in the lungs
Source: Wikipedia
Amorph. content
Flowability
Roughness
Shape Density
Electrostatics
Particle sizeBlend uniformity
Bulk Powder
‘Structural’
ParticleSize
ShapeDensity
HardnessSurf. Area
FlowabilityCompressibilityBulk Density(Blend uniformity)
PolymorphismTrue Density
Surface Energy
Moisture Content
Classification of physico-chemical properties
6
ElectricalProp.
For further reading: Zeng, X.M. et al, Particulate Interactions in Dry Powder Formulations for Inhalation, Taylor & Francis, London 2001.
How to measure surface energetics?
7
Techniques available:
Atomic Force Microscopy Difficult to perform
Low reproducibility
Wettability (Contact Angle) Poor reproducibility on powders
Limited sensitivity
Vapour Sorption IGC
Gravimetric Vapour Sorption (DVS)
Slide adapted with permission of Surface Measurement Systems, UK
Overview8
Introduction – Respiratory diseases and inhalation devices
Study I – Understanding of granulation behaviour
Study II – Morphology changes upon micronisation
Study III – Interaction of drug substance and propellant
Conclusions
Case Study: Granulation of glass beads9
Materials Model “Active”: Hydrophilic and hydrophobic glass
beads of two different particle sizes
Binders: Hydroxypropylcellulose (HPC)
Granule Properties Fluidized bed granulation
Particle size distribution measurements and Imaging
Goal Use IGC to measure surface energetics of individual
components (drugs and binders) and correlate to granulation behaviour
Slide adapted with permission of Surface Measurement Systems, UK
Source: Stepanek, F. and Thielmann, F., Powder Techn. (2008), 181 (2), 160-168
Case Study: Granulation of glass beads10
Hydrophilic glass beads show higher disp. surface energies than hydrophobic
20
25
30
35
40
AF AF225 HPC
Dis
pers
ive
Sur
face
Ene
rgy
[mJ/
m2]
Slide adapted with permission of Surface Measurement Systems, UK
Case Study: Granulation of glass beads
0
5
10
15
20
25
AF primary AF-225 primary HPC
Fre
e en
ergy
of d
esor
ptio
n [k
J/m
ol]
DichloromethaneAcetonitrileAcetoneEthyl acetateEthanol
11
Specific free energies show “fingerprint” of beads and binder
Slide adapted with permission of Surface Measurement Systems, UK
12
Granules from hydrophilic beads
Contact angle of binder solution: 0’ (complete wetting)
Case Study: Granulation of glass beads
Slide adapted with permission of Surface Measurement Systems, UK
Case Study: Granulation of glass beads
13
Granules from hydrophobic beads
Contact angle of binder solution: 114+/-6’
Slide adapted with permission of Surface Measurement Systems, UK
Case Study: Granulation of glass beads
14
Particle size distribution
0
5
10
15
20
25
30
35
40
500
425
355
300
250
180
150
1069075
Sieve cut [µm]
Fra
ctio
n re
tain
ed [
%] AF225
AF
hydrophilic hydrophobic
Slide adapted with permission of Surface Measurement Systems, UK
Case Study: Granulation of glass beads
15
Hydrophilic granules show finger print of HPCHydrophobic granules a mixture of HPC and beads
0
5
10
15
20
25
AF granules AF-225granules
HPC
Fre
e en
ergy
of d
esor
ptio
n [k
J/m
ol] Dichloromethane
AcetonitrileAcetoneEthyl acetateEthanol
Slide adapted with permission of Surface Measurement Systems, UK
Case Study: Granulation of glass beads - Results
16
Binder appears to “spread” on hydrophilic glass beads which results in “coating”.
Hydrophobic glass beads show “islands” of binder and solid bridges can be formed.
Due to spreading of binder little granulation occurs with hydrophilic glass beads and mean particle size is rather small.
Hydrophobic glass beads show bigger granules as solid bridges can be formed although size distribution is wide due to non-optimised granulation conditions.
Source: Stepanek, F. and Thielmann, F., Powder Techn. (2007), in press
Slide adapted with permission of Surface Measurement Systems, UK
iGC – Concentration Ranges
17
Am
ount
Ads
orbe
d
Elutant (Probe Molecule) Concentration
Infinite Dilution
Henry Region
BET Region
Finite Dilution
Usually pulse IGC is carried out at Infinite Dilutioni.e in the Henry Region
Slide adapted with permission of Surface Measurement Systems, UK
Determination of Surface Energy Distributions
18
Energy Distribution of Aspirin19
Disp. Surface Energy Profile
333435363738
0 0.2 0.4 0.6 0.8 1
n/nm [-]
gam
ma
d [
mJ/
m²]
Slide adapted with permission of Surface Measurement Systems, UK
J. Heng, A. Bismarck, A. Lee, K. Wilson and D. Williams, J. Pharm. Sci., 96, 2134-2144 (2007)
A. E. Jefferson, George D. Wang, D. J. Burnett, F. Thielmann, and J. Y. Y. Heng, Proceedings of Annual AAPS Meeting (2011)
Overview20
Introduction – Respiratory diseases and inhalation devices
Study I – Understanding of granulation behaviour
Study II – Morphology changes upon micronisation
Study III – Interaction of drug substance and propellant
Conclusions
Drug Product Manufacturing21
Air jet milling of API/ Dry blending
Spray-drying
(Spray) freeze-drying
SCF technology
Controlled crystallisation (e.g. ultrasonic)
Ultrasound assisted
Precipitation
Milling and Micronization Reduction of particle size by
mechanical force (stress) Advantage: universal, easy and
cheap Disadvantage: Process conditions need to be
carefully controlled Impact on morphology and
generation of amorphous material
Potential stabililty issues Mechanical properties of
materials as well as particle roughness and shape affected
22
Case Study: Impact of milling on β D-mannitol properties
23
Material Milled and unmilled β-D-mannitol
Investigation Ball-milled, different size fractions collected
Sieving of unmilled material to obtain similar sizefractions (elimination particle size effects)
Goal Correlation of aspect ratios and surface energetics
(determined by contact angle with single crystals) with IGC results obtained on powder in different particle size
Understanding of fractioning/ breakage mechanism duringmilling
Slide adapted with permission of Surface Measurement Systems, UK
24
Impact of milling on β D-mannitol properties
Molecular structure of D-mannitol Crystal habit of D-mannitol
Impact of milling on β D-mannitol properties
Milling reduces particle aspect ratio (shorter crystals). The bounding rectangular width is used here as a particle size parameter for sieved particles.
Milling increases BET specific surface area. However, the surface area within one group hardly changes, this is attributed to the inefficiency of sieving for needle-shaped particles.
25
Impact of milling on β D-mannitol properties
For needle-shaped crystals like D-mannitol, the weakest attachment energy crystal plane (010) is notpreferentially exposed.
Due to geometric effect, crystals fracture along the shortest axis (011) upon milling, resulting in a decrease in dispersive surface energy.
26
27
Impact of milling on β D-mannitol properties
Disp. Surface Energy (mJ/m2) Sieve fraction (µm) Aspect ratio
47.4 355-250 2.50747.2 250-180 2.48445.4 180-125 2.33744.8 125-63 2.092
Disp. surface energy shows small change with particle size and aspect ratio.
Disp. surface energy distribution confirms trends and shows that change is small due to small differences in energy of the crystal facets.
‘Infinite dilution’ ~ high energy sites
D.J. Burnett, M. Naderi, Raimundo Ho, J. Heng, F.Thielmann, A. Keith and G. Thiele, Proceedings of Annual AAPS Meeting (2011)
Overview28
Introduction – Respiratory diseases and inhalation devices
Study I – Understanding of granulation behaviour
Study II – Morphology changes upon micronisation
Study III – Interaction of drug substance and propellant
Conclusions
Drug-propellant interactions in MDI’s
• Materials• Drug substance: Salbutamol sulphate (SS),
salmeterol xinafoate (SX) and budesonide (BD)
• Propellants: HFA134a and HFA227
• Goal• Use IGC to measure surface energetics of
individual drug substances to estimate drug-drug interactions
• Measure specific interactions between drug substance and propellant directly
• Look at the impact of different background RH
29
30
Drug-propellant interactions in MDI’s
Slide adapted with permission of Surface Measurement Systems, UK
Dispersive surface energies (mJ/m2) for budesonide (BD), salbutamol sulphate (SS) and salmeterol xinafoate (SX) as well as specific free energies (kJ/Mol) of interaction with HFA 134a and 227.
31
Drug-propellant interactions in MDI’s
Slide adapted with permission of Surface Measurement Systems, UK
Change in the dispersive contribution of the surface energy (mJ/m2) of salbutamol sulphate with increasing humidity.
32
Drug-propellant interactions in MDI’s
Slide adapted with permission of Surface Measurement Systems, UK
Change in the specific free energy (kJ/Mol) of HFA 134a and 227 with increasing humidity for salbutamol sulphate.
33
Drug-propellant interactions in MDI’s Cohesion force decreases in the sequence:
BD>SS>SX. All three components show a stronger
interaction with the slightly more polar HFA 134a.
An increase in humidity reduces the drug-propellant interaction for salbutamol sulphatemore significantly than it affects the drug-drug interaction causing a potential reduction of suspension stability.
It is important to keep the moisture content of the drug substance as well as the moisture sorption during the formulation process low.
F. Thielmann M. Naderi, P. Jannick, Proceedings of Drug Delivery to the Lungs Symposium (2006)
Conclusions34
IGC is a useful tool to complement physico-chemical characterisation of pharmaceutical raw materials and products as well as to gain increased process understanding.
Surface energy measurements can be used to understand changes in morphology as shown in the case of Mannitol fracturing upon milling.
Adhesion/ cohesion balances derived from surface energy measurements can help to understand the suspension stability in MDI formulations
Surface energies are related to wetting properties and are therefore a good indicator for coating/ granulation behavior.
Inolytix IGC Symposium, June 2015
Acknowledgements
• My colleagues at Novartis, Switzerland• Dr Daniel Burnett, Surface Measurement
Systems Ltd. USA• Dr Jerry Heng, Imperial College, London,
UK• Peter Jannick, Solvay Fluor, Germany
35